Journal

What favourable Heidi scribe research establishes, what it does not, and why clinical agents need tests beyond documentation quality.

Why meaningful oversight of Heidi II requires more than an approval button, and how to test whether clinicians can challenge an incorrect proposal.

What Heidi II announced in September 2026, where its agents are available, and the evidence needed to assess their clinical value.

A hypothetical Heidi Work error raises a practical question: can clinicians understand the failure, recover the work and narrow reliance appropriately?

Heidi Work could become a practice-wide habit only if its delegated work fits shared routines, remains visible and survives beyond an individual champion.

Greater AI autonomy makes workflow specification, exception recognition and appropriate intervention important skills for clinicians to practise.

Patient acceptance of Heidi Work may depend on the task, recognition of individual circumstances and a workable route to human help.

Heidi Work needs adoption measures that distinguish quiet, reliable task completion from abandonment, repeated checking and rescue work.

If Heidi Work releases clinical capacity, its adoption may depend on whether that capacity becomes better care, less overtime or additional workload.

Heidi Work's adoption challenge is turning a completed AI task into a workflow clinicians can delegate without unnecessarily repeating the work.

A hypothetical £30 million TORTUS Series A would matter through product, evidence and implementation milestones, not through a cross-currency funding league table.

TORTUS Health adds a patient-facing care model to the earlier competitive scenarios, changing the questions Heidi, Tandem and clinical AI buyers should ask.